Radiation therapy for incompletely resected canine mast cell tumors.
The records of 56 dogs treated with megavoltage radiation for mast cell neoplasia were reviewed to determine the efficacy of this treatment modality. Total radiation dose ranged from 45 to 57 Gray (Gy), dose per fraction ranged from 3.0 to 4.0 Gy, and radiation treatment time ranged from 14-28 days. Median disease free interval (95% CI) was 32.7 (19-70) months. Median disease free interval for dogs older than 7.5 years was 15 (lower limit 7) months as compared to 62 (lower limit 20) for dogs younger than 7.5 years of age (p = 0.006). Median disease free interval for dogs with measurable disease was 12 (lower limit 5) months as compared to 54 (32-70) months for dogs with microscopic disease (p = 0.006). Radiation treatment time was also significantly related to disease free interval. Median disease free interval for dogs treated longer than 22 days was 12 (7-19) months as compared to greater than 50 (lower limit 20) months for dogs treated in 22 or fewer days (p < 0.001). This appeared to be due to more recurrences in dogs treated with 3-per-week fractionation and suggests that tumor proliferation in the interfraction interval may be important. Sex, tumor location, histologic grade, WHO clinical stage, number of radiation fractions, total radiation dose, and dose-per-fraction, as well as the following "yes/no" variables: steroids given, surgery prior to radiation, lymph nodes irradiated, and development of another mast cell tumor did not appear to influence median disease free interval or survival. Data presented herein support megavoltage radiation as an effective treatment for canine mast cell neoplasia, and suggest that disease free interval in dogs treated with daily fractions may be longer than that achieved with alternating day fractions.
LaDue
T
T
Department of Companion Animal and Special Species Medicine, College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA.
Price
G S
GS
Dodge
R
R
Page
R L
RL
Thrall
D E
DE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000367:Age Factors; D000818:Animals; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D004285:Dogs; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D008198:Lymph Nodes / Q000528:radiation effects; D008207:Lymphatic Metastasis / Q000532:radiotherapy; D008297:Male; D012515:Mast-Cell Sarcoma / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000662:veterinary; D009367:Neoplasm Staging / Q000662:veterinary; D018365:Neoplasm, Residual / Q000532:radiotherapy / Q000662:veterinary; D016609:Neoplasms, Second Primary / Q000473:pathology / Q000662:veterinary; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011879:Radiotherapy Dosage / Q000662:veterinary; D011882:Radiotherapy, High-Energy / Q000662:veterinary*; D012189:Retrospective Studies; D012737:Sex Factors; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000662:veterinary*; D015996:Survival Rate; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D003037:Cobalt Radioisotopes; D019275:Radiopharmaceuticals